Kappa-opioid receptors couple to inwardly rectifying potassium channels when coexpressed by Xenopus oocytes

Mol Pharmacol. 1995 Mar;47(3):551-7.

Abstract

Xenopus oocytes expressed kappa-opioid specific binding sites after injection of cRNA prepared from a clone of the rat kappa-opioid receptor. Coinjection of kappa receptor cRNA with cRNA coding for a G protein-linked, inwardly rectifying, K+ channel (GIRK1, or KGA) resulted in oocytes that responded to the kappa agonist U-69593 by activating a large (1.0-1.5-microA) K+ current. U-69593 exhibited an EC50 of 260 +/- 50 nM and was blocked by the opioid antagonists norbinaltorphimine and naloxone. The kappa agonist bremazocine was 200-fold more potent than U-69593 in eliciting K+ current but exhibited a partial agonist profile in this expression system. The present results indicate that stimulation of inwardly rectifying K+ channels may be a potential effector mechanism for kappa-opioid receptors.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Base Sequence
  • Benzeneacetamides*
  • Binding Sites
  • Cloning, Molecular
  • Electrophysiology
  • Female
  • GTP-Binding Proteins / genetics
  • GTP-Binding Proteins / metabolism
  • Ion Channel Gating / drug effects
  • Molecular Sequence Data
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Oocytes / metabolism*
  • Oocytes / ultrastructure
  • Potassium Channels / drug effects
  • Potassium Channels / genetics
  • Potassium Channels / metabolism*
  • Pyrrolidines / pharmacology
  • RNA, Complementary / administration & dosage
  • RNA, Complementary / genetics
  • Rats
  • Receptors, Opioid, kappa / genetics
  • Receptors, Opioid, kappa / metabolism*
  • Xenopus

Substances

  • Benzeneacetamides
  • Potassium Channels
  • Pyrrolidines
  • RNA, Complementary
  • Receptors, Opioid, kappa
  • norbinaltorphimine
  • Naltrexone
  • GTP-Binding Proteins
  • U 69593